Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
Topp, Max S. (Universitätsklinikum Würzburg)
Gökbuget, Nicola (Goethe University)
Zugmaier, Gerhard (Amgen GmbH)
Stein, Anthony S. (City of Hope Medical Center (Duarte, Estats Units d'Amèrica))
Dombret, Hervé (Saint Louis Hospital. University of Paris)
Chen, Yuqi (Amgen. Inc)
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Bargou, Ralf C. (Comprehensive Cancer Center Mainfranken. University Hospital Würzburg)
Horst, Heinz-August (Universitätsklinikum Schleswig-Holstein)
Kantarjian, Hagop M (The University of Texas MD Anderson Cancer Center)
Universitat Autònoma de Barcelona

Date:	2021
Abstract:	Background: Blinatumomab is a CD19 BiTE (bispecific T-cell engager) immuno-oncology therapy that mediates the lysis of cells expressing CD19. Methods: A pooled analysis of long-term follow-up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome-negative, relapsed/refractory B-cell precursor acute lymphoblastic leukemia was conducted. Results: A total of 259 patients were included in the analysis. The median overall survival (OS) among all patients, regardless of response, was 7. 5 months (95% confidence interval [CI], 5. 5-8. 5 months); the median follow-up time for OS was 36. 0 months (range, 0. 3-60. 8 months). The median relapse-free survival (RFS) among patients who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) in the first 2 cycles (n = 123) was 7. 7 months (95% CI, 6. 2-10. 0 months); the median follow-up time for RFS was 35. 0 months (range, 9. 5-59. 5 months). OS and RFS plateaued with 3-year rates of 17. 7% and 23. 4%, respectively. The cumulative incidence function of the time to relapse, with death not due to relapse considered a competing risk, for patients who achieved a CR/CRh within 2 cycles of treatment also plateaued with a 3-year relapse rate of 59. 3%. For patients who achieved a CR/CRh with blinatumomab followed by allogeneic hematopoietic stem cell transplantation while in continuous CR, the median OS was 18. 1 months (95% CI, 10. 3-30. 0 months) with a 3-year survival rate of 37. 2%. Conclusions: These data suggest that long-term survival is possible after blinatumomab therapy. Lay Summary: Immuno-oncology therapies such as blinatumomab activate the patient's own immune system to kill cancer cells. This study combined follow-up data from 2 blinatumomab-related clinical trials to evaluate long-term survival in patients with relapsed and/or refractory B-cell precursor acute lymphoblastic leukemia at high risk for unfavorable outcomes. Among patients who achieved a deep response with blinatumomab, one-third lived 3 years or longer. These findings suggest that long-term survival is possible after treatment with blinatumomab.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Acute lymphoblastic leukemia (ALL) ; Bispecific T-cell engager (BiTE) ; Blinatumomab ; Overall survival
Published in:	Cancer, Vol. 127 Núm. 4 (15 2021) , p. 554-559, ISSN 1097-0142

DOI: 10.1002/cncr.33298
PMID: 33141929

6 p, 186.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles